Inhibrx Biosciences (INBX) Accounts Payables (2023 - 2025)
Historic Accounts Payables for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $6.8 million.
- Inhibrx Biosciences' Accounts Payables fell 4524.66% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 4524.66%. This contributed to the annual value of $9.2 million for FY2024, which is 1560.16% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Accounts Payables is $6.8 million, which was down 4524.66% from $8.3 million recorded in Q2 2025.
- Inhibrx Biosciences' 5-year Accounts Payables high stood at $13.0 million for Q2 2024, and its period low was $6.8 million during Q3 2025.
- In the last 3 years, Inhibrx Biosciences' Accounts Payables had a median value of $9.2 million in 2024 and averaged $9.9 million.
- Its Accounts Payables has fluctuated over the past 5 years, first crashed by 1560.16% in 2024, then crashed by 4524.66% in 2025.
- Over the past 3 years, Inhibrx Biosciences' Accounts Payables (Quarter) stood at $11.0 million in 2023, then decreased by 15.6% to $9.2 million in 2024, then dropped by 26.74% to $6.8 million in 2025.
- Its last three reported values are $6.8 million in Q3 2025, $8.3 million for Q2 2025, and $8.9 million during Q1 2025.